Atazanavir/ritonavir-based combination antiretroviral therapy for treatment of HIV-1 infection in adults

被引:38
作者
Achenbach, Chad J. [1 ,2 ]
Darin, Kristin M. [1 ,2 ]
Murphy, Robert L. [1 ,2 ,3 ]
Katlama, Christine [3 ,4 ]
机构
[1] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
[2] Northwestern Univ, Ctr Global Hlth, Chicago, IL 60611 USA
[3] Univ Paris 06, Paris, France
[4] Grp Hosp Pitie Salpetriere, AP HP, Serv Malad Infect & Trop, F-75634 Paris, France
关键词
antiretroviral therapy; atazanavir; HIV; protease inhibitor; ritonavir; HUMAN-IMMUNODEFICIENCY-VIRUS; RITONAVIR-BOOSTED ATAZANAVIR; NAIVE HIV-1-INFECTED PATIENTS; TWICE-DAILY LOPINAVIR/RITONAVIR; ONCE-DAILY ATAZANAVIR/RITONAVIR; STEADY-STATE PHARMACOKINETICS; LOW-DOSE RITONAVIR; HEPATITIS-C VIRUS; PROTEASE INHIBITOR; UNBOOSTED ATAZANAVIR;
D O I
10.2217/FVL.10.89
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
In the past 15 years, improvements in the management of HIV infection have dramatically reduced morbidity and mortality. Similarly, rapid advances in antiretroviral medications have resulted in the possibility of life-long therapy with simple and tolerable regimens. Protease inhibitors have been important medications in regimens of combination antiretroviral therapy for the treatment of HIV. One of the recommended and commonly used therapies in this class is once-daily-administered atazanavir, pharmacologically boosted with ritonavir (atazanavir/r). Clinical studies and practice have shown these drugs, in combination with other antiretroviral agents, to be potent, safe and easy to use in a variety of settings. Atazanavir/r has minimal short-term toxicity, including benign bilirubin elevation, and has less potential for long-term complications of hyperlipidemia and insulin resistance compared with other protease inhibitors. A high genetic barrier to resistance and a favorable resistance profile make it an excellent option for initial HIV treatment or as the first drug utilized in the protease inhibitors class. Atazanavir/r is also currently being studied in novel treatment strategies, including combinations with new classes of antiretrovirals to assess nucleoside reverse transcriptase inhibitor-sparing regimens. In this article we review atazanavir/r as a treatment for HIV infection and discuss the latest information on its pharmacology, efficacy and toxicity.
引用
收藏
页码:157 / 177
页数:21
相关论文
共 115 条
  • [1] Aberg J, 2010, 18 INT AIDS C VIENN
  • [2] AGARWALA S, 2003, 2 IAS C HIV PATH TRE
  • [3] AGARWALA S, 2005, 12 C RETR OPP INF MA
  • [4] AGARWALA S, 2007, 14 C RETR OPP INF CA
  • [5] AGARWALA S, 2007, 8 INT WORKSH CLIN PH
  • [6] AGARWALA S, 2005, 6 INT WORKSH CLIN PH
  • [7] Strong CD4 Th1 responses to HIV and hepatitis C virus in HIV-infected long-term non-progressors co-infected with hepatitis C virus
    Alatrakchi, N
    Di Martino, V
    Thibault, V
    Autran, B
    [J]. AIDS, 2002, 16 (05) : 713 - 717
  • [8] Atazanavir-containing renal calculi in an HIV-infected patient
    Anderson, Peter L.
    Lichtenstein, Kenneth A.
    Gerig, Nel E.
    Kiser, Jennifer J.
    Bushman, Lane R.
    [J]. AIDS, 2007, 21 (08) : 1060 - 1062
  • [9] Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors
    Anderson, Peter L.
    Aquilante, Christina L.
    Gardner, Edward M.
    Predhomme, Julie
    McDaneld, Patrick
    Bushman, Lane R.
    Zheng, Jia-Hua
    Ray, Michelle
    MaWhinney, Samantha
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2009, 64 (05) : 1071 - 1079
  • [10] [Anonymous], UNAIDS Report on the Global AIDS Epidemic 2010